Want to see ALLO full AI Analyst Report?
Top Page
Allogene Therapeutics
(NASDAQ:ALLO)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.00
▲(14.94% Upside)
Action:Reiterated
Date:06/23/26
ALLO scores in the low-to-mid range primarily due to very weak financial performance (minimal revenue, sustained losses, and significant cash burn) despite modest leverage. The score is supported by constructive earnings-call takeaways—early clinical signals and an extended cash runway—but tempered by preliminary data risk and increased expense guidance. Technicals are neutral-to-slightly weak, and valuation offers limited support given negative earnings and no dividend.
Positive Factors
Robust early efficacy signals
Clear MRD and ctDNA pharmacodynamic responses provide biological proof-of-concept for cema-cel. Durable biological signals can materially de-risk pivotal readouts, strengthen regulatory discussions, and support label differentiation versus observation or competing therapies over the next 2–6 months.
Negative Factors
No recurring product revenue
Absence of product revenue means ongoing reliance on financings and partnerships to fund development. Persistent operating losses reduce financial flexibility and increase execution risk for manufacturing scale-up and commercialization planning over the coming 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Robust early efficacy signals
Clear MRD and ctDNA pharmacodynamic responses provide biological proof-of-concept for cema-cel. Durable biological signals can materially de-risk pivotal readouts, strengthen regulatory discussions, and support label differentiation versus observation or competing therapies over the next 2–6 months.
Read all positive factors
Allogene Therapeutics (ALLO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$693.76M
Dividend YieldN/A
Average Volume (3M)8.88M
Price to Earnings (P/E)―
Beta (1Y)1.69
Revenue GrowthN/A
EPS Growth37.45%
CountryUS
Employees151
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.77
Shares Outstanding345,154,570
10 Day Avg. Volume5,424,436
30 Day Avg. Volume8,884,984
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.03
Price to Sales (P/S)0.00
P/FCF Ratio-2.02
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside474.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.72
Revenue Forecast (FY)$6.00K
Allogene Therapeutics Business Overview & Revenue Model
Company Description
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their de...
How the Company Makes Money
Allogene Therapeutics does not have recurring product revenue from marketed therapies; its primary revenue, when reported, has historically come from collaboration-related arrangements rather than commercial sales. The company’s monetization model...
Allogene Therapeutics Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful early clinical progress — notably a strong MRD clearance signal and ctDNA reduction for cema-cel, favorable outpatient safety signals, encouraging early activity and tolerability for ALLO-329, operational scale-up and a strengthened balance sheet that extends runway into 2029. Major caveats include small interim sample size, the preliminary nature of surrogate biomarker results pending EFS validation, continued dose escalation and limited ALLO-329 maturity, and increased 2026 operating expense guidance. On balance, the call emphasized advancing, differentiated clinical data and execution momentum while acknowledging near-term clinical and financial uncertainties.Positive Updates
ALPHA3 Interim MRD Efficacy Signal
Interim futility analysis (24 patients) showed MRD clearance of 58.3% for cema-cel vs 16.7% for observation — an absolute difference of 41.6 percentage points, supporting biological activity in first-line consolidation for LBCL.
Negative Updates
Preliminary Nature and Small Size of Interim Data
ALPHA3 interim results are based on a small 24-patient analysis and rely on the assumption that MRD clearance will translate to EFS benefit — EFS impact remains unconfirmed until planned interim/primary analyses.
Read all updates
Q1-2026 Updates
Positive
Negative
ALPHA3 Interim MRD Efficacy Signal
Interim futility analysis (24 patients) showed MRD clearance of 58.3% for cema-cel vs 16.7% for observation — an absolute difference of 41.6 percentage points, supporting biological activity in first-line consolidation for LBCL.
Read all positive updates
Company Guidance
Allogene reported a March 31 cash balance of $266.9M and approximately $200.4M of gross proceeds from an April offering, extending its cash runway into Q1 2029; Q1 spend included R&D of $32M (inc. $2.7M non‑cash stock comp), G&A of $14.1M (inc. $5.6M non‑cash), and a net loss of $42.6M or $0.18/share (inc. $8.3M non‑cash). Management modestly raised 2026 operating cash expense guidance from ~ $150M to ~ $165M and GAAP operating expense guidance from ~ $210M to ~ $225M (including an estimated ~$35M of non‑cash stock comp), excluding any M&A impact. Key clinical timing guidance: complete ALPHA3 enrollment by end‑2027 with an interim EFS analysis in mid‑2027 and primary EFS analysis in mid‑2028 (BLA filing to follow as appropriate); ALPHA3 is now enrolling at >60 sites with planned expansion to >80 globally. They also expect an ALLO‑329 update in Q4 2026 after initial dosing (9 patients to date: 3 at 20M cells + cyclophosphamide, 3 at 40M + cyclophosphamide, 3 at 20M without lymphodepletion); management noted the ALPHA3 interim futility (n=24) showed a 58.3% vs 16.7% MRD clearance (41.6‑point absolute difference) and median ctDNA −~98% at day 45 versus +>26% in observation, which they say supports execution within the provided financial runway.Allogene Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 22.00K | 95.00K | 156.00K | 114.09M |
| Gross Profit | -77.25M | -12.36M | 22.00K | 95.00K | -14.14M | 114.09M |
| EBITDA | -160.41M | -177.45M | -243.33M | -313.07M | -326.12M | -171.60M |
| Net Income | -173.76M | -190.89M | -257.59M | -327.26M | -340.41M | -182.05M |
Balance Sheet | ||||||
| Total Assets | 395.96M | 415.90M | 548.71M | 642.84M | 821.58M | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 266.89M | 250.21M | 292.48M | 448.70M | 517.32M | 457.30M |
| Total Debt | 81.05M | 83.25M | 90.76M | 95.12M | 101.12M | 73.13M |
| Total Liabilities | 117.08M | 123.36M | 126.53M | 130.60M | 154.70M | 125.63M |
| Stockholders Equity | 278.88M | 292.54M | 422.18M | 512.23M | 666.88M | 925.20M |
Cash Flow | ||||||
| Free Cash Flow | -109.53M | -149.63M | -200.99M | -239.25M | -225.71M | -206.26M |
| Operating Cash Flow | -109.23M | -149.25M | -200.30M | -237.73M | -220.52M | -184.81M |
| Investing Cash Flow | 59.80M | 95.56M | 75.69M | 163.29M | 106.16M | 163.66M |
| Financing Cash Flow | 37.29M | 30.16M | 116.67M | 95.69M | 2.95M | 11.96M |
Allogene Therapeutics Technical Analysis
Positive
1.74
Price Trends
1.96
Positive
2.13
Negative
1.89
Positive
Market Momentum
<0.01
Negative
60.54
Neutral
96.23
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLO, the sentiment is Positive. The current price of 1.74 is below the 20-day moving average (MA) of 1.86, below the 50-day MA of 1.96, and below the 200-day MA of 1.89, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.54 is Neutral, neither overbought nor oversold. The STOCH value of 96.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALLO.
Allogene Therapeutics Risk Analysis
Allogene Therapeutics disclosed 78 risk factors in its most recent earnings report. Allogene Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allogene Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $412.64M | 5.80 | 41.40% | ― | ― | ― | |
52 Neutral | $693.76M | -2.73 | -56.45% | ― | ― | 37.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $162.97M | -1.39 | -108.05% | ― | ― | 45.08% | |
44 Neutral | $360.47M | -6.30 | 72.64% | ― | 51.98% | 17.68% | |
43 Neutral | $302.01M | -1.22 | -181.70% | ― | ― | 17.61% |
* Healthcare Sector Average
ALLO
Allogene Therapeutics
2.10
1.07
103.88%
ABEO
Abeona Therapeutics
7.45
1.17
18.63%
FHTX
Foghorn Therapeutics
6.24
1.53
32.48%
TNYA
Tenaya Therapeutics
0.74
0.06
8.22%
NMRA
Neumora Therapeutics, Inc.
1.62
0.18
12.50%
Allogene Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
Allogene Launches ATM Offering to Bolster Capital Flexibility
Positive
Jun 22, 2026
At its June 18, 2026 annual meeting, Allogene Therapeutics’ stockholders elected three Class II directors to serve until the 2029 meeting, approved executive compensation on an advisory basis, and opted for annual say-on-pay votes, which the...
Executive/Board Changes
Allogene Therapeutics Names Zachary Roberts as New CEO
Positive
May 28, 2026
On May 28, 2026, Allogene Therapeutics’ board appointed Zachary Roberts, M.D., Ph.D., as president and chief executive officer, effective July 1, 2026, succeeding co-founder David Chang, M.D., Ph.D., whose last day in those roles will be Jun...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Allogene Highlights ALPHA3 Data and Extended Cash Runway
Positive
May 13, 2026
On May 12, 2026, Allogene terminated its exclusive license agreement with Overland Therapeutics covering four allogeneic CAR T targets in parts of Asia, relinquished a portion of its equity and governance rights, and now expects to hold about 3% o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.